M-Vax: An autologous, hapten-modified for human cancer

Expert Review of Vaccines

Volumn 3, Issue 5, 2004, Pages 521-527

  Berd, David ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autologous; Cyclophosphamide; Immunotherapy; Melanoma

Indexed keywords

2,4 DINITROPHENOL; BCG VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; HAPTEN; M VAX; MELANOMA VACCINE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER STAGING; CLINICAL RESEARCH; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INJECTION SITE; KIDNEY CARCINOMA; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; METASTASIS; OVARY CARCINOMA; PAPULE; PRIORITY JOURNAL; PUSTULE; RASH; STATISTICAL SIGNIFICANCE; SURGICAL RISK; SURVIVAL RATE; SYSTEMATIC REVIEW; TUMOR CELL; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; DINITROBENZENES; HAPTENS; HUMANS; HYPERSENSITIVITY, DELAYED; INFLAMMATION; LUNG NEOPLASMS; MELANOMA; NEOPLASM STAGING; T-LYMPHOCYTES;

EID: 7444242049     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.5.521     Document Type: Article

References (15)

1. DiFronzo LA, Gupta RK, Essner R et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J. Clin. Oncol. 20, 3242-3248 (2002). Clinical results of an allogeneic, whole-cell melanoma vaccine.
2. Pullarkat V, Lee PP, Scotland R et al. A Phase I trial of SD-9427 (Progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin. Cancer Res. 9, 1301 (2003). Perhaps the best results obtained with a peptide vaccine.
3. Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20, 4169-4180 (2002). Clinical trial of autologous, heat shock protein vaccine.
4. Ramarathinam L, Sarma S, Maric M et al. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross protected. J. Immunol 155, 5323-5329 (1995). Classic reference demonstrating that common tumor antigens do not usually mediate tumor rejection.
5. Berd D. Hapten-Modified Vaccines. In: Handbook of Cancer Vaccines. Morse MA, Clay TM, Lyerly HK (Eds). Humana Press, NJ, USA, 225-248 (2004). Recent, comprehensive review of the autologous, DNP-modified vaccine.
6. Weigle WO. The production of thyroiditis and antibody following injection of unaltered thyroglobulin without adjuvant into rabbits previously stimulated with altered thyroglobulin. J. Exp. Med. 122, 1049-1062 (1965). Classic reference demonstrating the hapten phenomenon.
7. Berd D, Sato T, Mastrangelo MJ. Effect of the dose and composition of an autologous, hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol. Immunother. 51, 320-326 (2002). Detailed description of the composition of autologous, DNP vaccines and the effect of composition on immune responses.
8. Berd D, Maguire HC Jr, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res, 44, 5439-5443 (1984). Original description of the immunopotentiating effects of cyclophosphamide in humans.
9. Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacological analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 22, 403-415 (2004). Most recent description of the immunology of the DNP vaccine and clinical results in Stage III postsurgical adjuvant patients
10. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol. Immunother. 41, 151-156 (1995). Demonstration of proinflammatory cytokine production in inflamed tumors after DNP-vaccine administration.
11. Berd D, Maguire HC Jr, Mastrangelo MJ, Murphy GF. Activation markers on T-cells infiltrating melanoma metastases after therapy with dinitrophenyl- conjugated vaccine. Cancer Immunol. Immunother. 39, 141-147 (1994). Early observation regarding the tumor inflammatory responses induced by the DNP vaccine with flow cytometry data.
12. Manne J, Mastrangelo MJ, Sato T, Berd D. T-cell receptor rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J. Immunol 169, 3407-3412 (2002). Demonstration of novel T-cell clones in inflamed tumors after DNP-vaccine administration.
13. Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int. J. Cancer 94, 531-539 (2001). Demonstration that DNP vaccine can induce regression of melanoma metastases.
14. Lee P, Wang F, Kuniyoshi J et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836-3847 (2001). Example of the difficulty of immunizing patients with peptide vaccines.
15. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 21, 873-886 (2003). Comprehensive review of the clinical results and problems with dendritic cell cancer vaccines.